Schizoaffective Disorder Clinical Trial
Official title:
Evaluating a Collaborative Care Model for the Treatment of Schizophrenia (EQUIP)
Policy makers and consumers are increasingly concerned about the quality and efficiency of
care provided to individuals with severe, chronic illnesses such as schizophrenia. These
illnesses are expensive to treat and present significant challenges to organizations that
are responsible for providing effective care. Occurring in 1% of the United States
population, schizophrenia accounts for 10% of permanently disabled people, and 2.5% of all
healthcare expenditures. Clinical practice guidelines have been promulgated. Schizophrenia
is treatable and outcomes can be substantially improved with the appropriate use of
antipsychotic medication, caregiver education and counseling, vocational rehabilitation, and
assertive treatment. However, in the VA and other mental health systems, many patients with
schizophrenia receive substandard care. Methods are needed that improve the quality of usual
care for this disorder while being feasible to implement at typical clinics.
To date, most efforts to improve care for schizophrenia have focused on educating clinicians
or changing the financing of care, and have had limited success. We believe a more
fundamental approach should be tried. While there are many potential strategies, experience
in chronic medical illness and mental health support the efficacy of specific approaches.
Collaborative care models are one such approach. They are a blueprint for reorganizing
practice, and involve changes in division of labor and responsibility, adoption of new care
protocols, and increased attention to patients' needs. Although collaborative care models
have been successful in other chronic medical conditions, they have not yet been studied in
the treatment of schizophrenia.
We have developed a collaborative care model for schizophrenia that builds on work in other
disorders, and includes service delivery approaches that are known to be effective in
schizophrenia. The model focuses on improving treatment through assertive care management,
caregiver education and support, and standardized patient assessment with feedback of
information to psychiatrists. This project, "EQUIP" (Enhancing Quality Utilization In
Psychosis) is implementing collaborative care and evaluating its effectiveness in
schizophrenia.
Background:
Policy makers and consumers are increasingly concerned about the quality and efficiency of
care provided to individuals with severe, chronic illnesses such as schizophrenia. These
illnesses are expensive to treat and present significant challenges to organizations that
are responsible for providing effective care. Occurring in 1% of the United States
population, schizophrenia accounts for 10% of permanently disabled people, and 2.5% of all
healthcare expenditures. Clinical practice guidelines have been promulgated. Schizophrenia
is treatable and outcomes can be substantially improved with the appropriate use of
antipsychotic medication, caregiver education and counseling, vocational rehabilitation, and
assertive treatment. However, in the VA and other mental health systems, many patients with
schizophrenia receive substandard care. Methods are needed that improve the quality of usual
care for this disorder while being feasible to implement at typical clinics.
To date, most efforts to improve care for schizophrenia have focused on educating clinicians
or changing the financing of care, and have had limited success. We believe a more
fundamental approach should be tried. While there are many potential strategies, experience
in chronic medical illness and mental health support the efficacy of specific approaches.
Collaborative care models are one such approach. They are a blueprint for reorganizing
practice, and involve changes in division of labor and responsibility, adoption of new care
protocols, and increased attention to patients' needs. Although collaborative care models
have been successful in other chronic medical conditions, they have not yet been studied in
the treatment of schizophrenia.
We have developed a collaborative care model for schizophrenia that builds on work in other
disorders, and includes service delivery approaches that are known to be effective in
schizophrenia. The model focuses on improving treatment through assertive care management,
caregiver education and support, and standardized patient assessment with feedback of
information to psychiatrists. This project, "EQUIP" (Enhancing Quality Utilization In
Psychosis) is implementing collaborative care and evaluating its effectiveness in
schizophrenia.
Objectives:
The objective of this project was to implement the care model at two large VA mental health
centers, and evaluate its effect on clinicians, the organization of care, and treatment
appropriateness, utilization and outcomes in veterans with schizophrenia. We hypothesized
that this care model would increase provider adherence to treatment guidelines and improve
the quality of care. We planned to describe implementation of the model, and barriers and
facilitators to its implementation. We planned to evaluate the model by comparing treatment
under the care model with usual care. Changes in the structure of care were evaluated using
qualitative methods.
Methods:
EQUIP was a controlled trial of the care model. At two VA medical centers, clinicians (n=66)
and their patients (n=398) were randomized to an intervention or a control condition. In the
intervention group, a chronic care model was implemented for 15 months. Before, during, and
after implementation, surveys and semi-structured interviews were conducted with clinicians
and managers to assess their clinical practices, competencies, expectations, experiences,
and observations concerning the implementation. Data sources included patient interviews,
clinician interviews, and data from VistA. The feasibility of more broadly implementing the
collaborative care model was assessed utilizing qualitative and quantitative information
about the model's strengths and weaknesses, factors that facilitated/impeded implementation,
direct costs of implementation and maintenance, and effects on treatment service
utilization.
Status:
Data collection is complete. Data analyses are ongoing. Reports are being written and
published. Presentations are being given.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT01878513 -
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis
|
N/A | |
Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
Not yet recruiting |
NCT04551027 -
Assessing the Effect of Compensatory Cognitive Intervention Among People With Severe Mental Illness
|
N/A | |
Completed |
NCT02901587 -
Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT02796144 -
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
|
Phase 4 | |
Completed |
NCT02160249 -
RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia)
|
N/A | |
Recruiting |
NCT02986490 -
Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs
|
N/A | |
Completed |
NCT02417142 -
Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
|
Phase 4 | |
Terminated |
NCT02234752 -
Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia
|
Phase 2 | |
Completed |
NCT02091388 -
Bioavailability of LY03004 and Risperdal® Consta®
|
Phase 1 | |
Completed |
NCT01975584 -
Neuroendocrine and Immune Response to Stress in Schizophrenia
|
N/A | |
Terminated |
NCT02149823 -
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
|
Phase 1 | |
Completed |
NCT01992393 -
Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)
|
N/A | |
Completed |
NCT01945333 -
Personalized and Scalable Cognitive Remediation Approaches
|
N/A | |
Completed |
NCT01658150 -
Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder
|
N/A | |
Completed |
NCT01683539 -
Understanding How Cognitive Remediation Works
|
N/A | |
Completed |
NCT01198353 -
Effectiveness of Ziprasidone for Patients With Schizophrenia
|
Phase 4 |